A second chance for avatrombopag in chemotherapy-induced thrombocytopenia

被引：0

作者：

Al-Samkari, Hanny ^{[1
,2
]}

Moore, Donald C. ^{[3
]}

机构：

[1] Massachusetts Gen Hosp, Div Hematol Oncol, Bartlett Hall Extens Off 133, Boston, MA 02114 USA

[2] Harvard Med Sch, Boston, MA USA

[3] Atrium Hlth, Levine Canc Inst, Dept Pharm, Charlotte, NC USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2025年 / 206卷 / 01期

关键词：

avatrombopag; chemotherapy-induced thrombocytopenia; persistent; romiplostim; thrombopoietin receptor agonist; ROMIPLOSTIM;

D O I：

10.1111/bjh.19861

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chemotherapy-induced thrombocytopenia (CIT) remains a common complication of cancer therapy with no approved available treatments in most of the world. Although a prior clinical trial of avatrombopag for CIT did not meet its primary end-point, a report from Galamaga and colleagues raises prospects for a second chance for avatrombopag in CIT, highlighting the differences between nadir and persistent CIT and the importance of patient selection in CIT treatment.

引用

页码：375 / 377

页数：3

共 50 条

[1] Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series
Galamaga, Robert
Johnston, Stephanie
Acosta, Cassaundra
BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (01) : 272 - 278
[2] Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment
Song, Andrew B.
Al-Samkari, Hanny
BRITISH JOURNAL OF HAEMATOLOGY, 2025, : 1062 - 1066
[3] Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors
Gao, Yanting
Liu, Qi
Shen, Yingying
Li, Yuzhu
Shao, Keding
Ye, Baodong
Shen, Yiping
Zhou, Yuhong
Wu, Dijiong
PLATELETS, 2022, 33 (07) : 1024 - 1030
[4] Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists
Al-Samkari, Hanny
BLOOD REVIEWS, 2024, 63
[5] Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia
Song, Andrew B. B.
Al-Samkari, Hanny
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (05) : 365 - 375
[6] Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia
Al-Samkari, Hanny
Soff, Gerald A.
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 437 - 448
[7] Efficacy and Safety of Avatrombopag in the Treatment of Chemotherapy-Induced Thrombocytopenia in Children with Acute Lymphoblastic Leukemia: A Retrospective Study Author
Chen, Libai
Yang, Huiyan
Zhang, Lei
Ruan, Yongsheng
Wen, Jianyun
Wu, Xuedong
BLOOD, 2023, 142
[8] Romiplostim for management of chemotherapy-induced thrombocytopenia
R. Parameswaran
M. Lunning
S. Mantha
S. Devlin
A. Hamilton
G. Schwartz
G. Soff
Supportive Care in Cancer, 2014, 22 : 1217 - 1222
[9] Romiplostim for management of chemotherapy-induced thrombocytopenia
Parameswaran, R.
Lunning, M.
Mantha, S.
Devlin, S.
Hamilton, A.
Schwartz, G.
Soff, G.
SUPPORTIVE CARE IN CANCER, 2014, 22 (05) : 1217 - 1222
[10] An evaluation of avatrombopag for the treatment of thrombocytopenia
Virk, Zain Mohammed
Kuter, David J.
Al-Samkari, Hanny
EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (03) : 273 - 280

← 1 2 3 4 5 →